文献速递头颈外科咽喉与嗓音

商业保险喉癌患者的治疗、短期结局与费用分析

Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients.
PubMed 文献 · Laryngoscope · 2017-07-07

基于MarketScan商业保险数据库2010至2012年10969例喉癌患者的回顾性横断面分析,放化疗与声门上型肿瘤、治疗前胃造瘘及酒精滥用相关;治疗相关并发症发生率为23%,复发或持续病变率为23%。在控制并发症与挽救治疗等变量后,放化疗的初始治疗费用与1年总费用高于其他治疗类别,高手术量诊疗与手术患者费用降低相关。

要点

  • 放化疗与声门上型肿瘤、治疗前胃造瘘相关,且医疗并发症风险升高。
  • 治疗相关并发症发生率23%,其中医疗并发症22%、手术并发症7%。
  • 复发或持续病变者中46%接受挽救手术,放化疗后挽救手术可能性降低。

核心结论

  • 在65岁以下商业保险喉癌患者中,放化疗与费用增加、治疗相关医疗并发症增多及手术挽救可能性降低相关。
  • 高手术量诊疗与手术患者初始治疗费用及1年费用降低相关,非手术治疗患者中未见此差异。

研究设计与样本

  • 回顾性横断面分析,数据来源为MarketScan Commercial Claim and Encounters数据库。
  • 纳入2010至2012年诊断为喉癌的患者10969例,采用交叉表与多因素回归分析。

主要发现

  • 放化疗与声门上型肿瘤相关(RRR=5.9 [4.4-7.8]),与治疗前胃造瘘相关(RRR=4.0 [2.7-6.1]),与酒精滥用相关(RRR=0.5 [0.3-0.9])。
  • 治疗相关并发症发生于23%的患者,医疗并发症22%,手术并发症7%。
  • 放化疗(OR=3.7 [2.6-5.2])、大型手术(OR=4.9 [3.5-6.8])、重建(OR=7.7 [4.1-14.7])及晚期合并症(OR=9.7 [5.7-16.5])与急性并发症相关。
  • 复发或持续病变发生于23%的患者,与高容量诊疗相关(OR=1.4 [1.1-1.8])。
  • 复发或持续病变者中46%接受挽救手术,声门上型病变(OR=0.5 [0.4-0.8])及放化疗后(OR=0.4 [0.2-0.6])挽救手术可能性较低。

关键数值与推荐

  • 治疗相关并发症总发生率为23%,医疗并发症22%,手术并发症7%。
  • 复发或持续病变率为23%,其中46%接受挽救手术。

临床怎么用

  • 喉癌治疗选择需权衡费用与并发症风险,放化疗患者应关注医疗并发症及挽救手术可能性降低。
  • 高手术量诊疗可能降低手术患者的初始治疗与1年费用,可作为价值与质量讨论的参考。

局限性

  • 数据仅限65岁以下商业保险人群,结论外推受限。
  • 为回顾性横断面分析,证据等级为2c,无法确立因果关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To examine associations between treatment, complications, and costs in patients with laryngeal cancer. STUDY DESIGN: Retrospective cross-sectional analysis of MarketScan Commercial Claim and Encounters data. METHODS: We evaluated 10,969 patients diagnosed with laryngeal cancer from 2010 to 2012 using cross-tabulations and multivariate regression. RESULTS: Chemoradiation was significantly associated with supraglottic tumors (relative risk ratio [RRR] = 5.9 [4.4-7.8]), pretreatment gastrostomy (RRR = 4.0 [2.7-6.1]), and alcohol abuse (RRR = 0.5 [0.3-0.9]). Treatment-related complications occurred in 23% of patients, with medical complications in 22% and surgical complications in 7%. Chemoradiation (odds ratio [OR] = 3.7 [2.6-5.2]), major surgical procedures (OR = 4.9 [3.5-6.8]), reconstruction (OR = 7.7 (4.1-14.7)], and advanced comorbidity (OR = 9.7 [5.7-16.5] were associated with acute complications. Recurrent/persistent disease occurred in 23% of patients and was associated with high-volume care (OR = 1.4 [1.1-1.8]). Salvage surgery was performed in 46% of patients with recurrent/persistent disease and was less likely for supraglottic disease (OR = 0.5 [0.4-0.8]) and after chemoradiation (OR = 0.4 [0.2-0.6]). Initial treatment and 1-year overall costs for chemoradiation were higher than all other treatment categories, after controlling for all other variables including complications and salvage. High-volume care was associated with significantly lower costs of care for surgical patients but was not associated with differences in costs of care for nonoperative treatment. CONCLUSIONS: In commercially insured patients <65 years old with laryngeal cancer, chemoradiation was associated with increased costs, an increased likelihood of treatment-related medical complications, and a reduced likelihood of surgical salvage. Higher-volume surgical care was associated with lower initial treatment and 1-year costs of care. These data have implications for discussions of value and quality in an era of healthcare reform. LEVEL OF EVIDENCE: 2c. Laryngoscope, 128:91-101, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Day AT, Chang HY, Quon H, et al. Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. Laryngoscope. 2017. PMID: 28685830. doi:10.1002/lary.26717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。